A5202: A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 A5202是一项IIIB期随机四臂研究，旨在比较开放标签利托那韦(RTV)增强型阿扎那韦(ATV)与依法林(EFV)联合每日服用恩曲他滨(FTC)/替诺福韦(TDF)或阿巴卡韦(ABC)/拉米夫定(3TC)以及部分盲用ABC/3TC与FTC/TDF联合RTV增强型ATV或EFV作为HIV-1感染初始治疗的疗效、安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5202 is a phase IIIB, randomized, four-arm study, comparing the efficacy, safety, and tolerability of open-lable ritonavir (RTV)-enhanced atazanavir (ATV) to efavirenze (EFV), in combination with either daily emtricitabine (FTC)/ tenofovir (TDF) or abacavir (ABC)/lamivudine (3TC) and of partially blinded ABC/3TC compared to FTC/TDF in combination with either RTV-enhanced ATV or EFV as initial therapy for HIV-1 infection.